Loading clinical trials...
Loading clinical trials...
A Phase Ib Multi-Center, Double-Blind, Randomized, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability and Immunogenicity of ACI-24 in Adults With Down Syndrome
Conditions
Interventions
ACI-24 low dose
ACI-24 high dose
+1 more
Locations
4
United States
St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics
Phoenix, Arizona, United States
UCSD Adult Down Syndrome Program
La Jolla, California, United States
Johns Hopkins University
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
March 1, 2016
Primary Completion Date
June 1, 2020
Completion Date
June 1, 2020
Last Updated
October 15, 2021
NCT04726241
NCT07234695
NCT07248267
NCT07244133
NCT07101523
NCT06512168
Lead Sponsor
AC Immune SA
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions